The Human Cancer PrimaCell™ 17: Thyroid Carcinoma Cells is for rapid (7-10 days) isolation and growth of human thyroid carcinoma cells from human thyroid carcinoma tissues. This system features an optimal condition of tissue dissociation system, Cancer OptiTDS™ that yields 6-8 times of single cells more than most of the tissue dissociation protocols published in the literature. In addition, this system ensures a high viability of the target cells with improved gradient contained in the culture medium.

Human Cancer PrimaCell™ 17 System (Cat No. 2-96041):
Human Cancer PrimaCell™ 17: Thyroid Carcinoma Cells Protocols
Human Cancer Tissue Preparation Buffer 17: Thyroid Carcinoma Cells
Human Cancer OptiTDS™ 17: Tissue Dissociation System
Human Cancer PrimaCell™ 17: Thyroid Carcinoma Cells Growth Medium
Human Cancer PrimaCell™ 17: Thyroid Carcinoma Cells Growth Supplements with Serum (for 500 ml medium)

References:

[1] Antonelli A, Ferrari SM, Fallahi P, Berti P, Materazzi G, Minuto M, Giannini R, Marchetti I, Barani L, Basolo F, Ferrannini E, Miccoli P. Thiazolidinediones and antiblastics in primary human anaplastic thyroid cancer cells. Clin Endocrinol (Oxf). 2009 Jun;70(6):946-53. Epub 2008 Sep 10.
[2] Antonelli A, Ferrari SM, Fallahi P, Berti P, Materazzi G, Barani L, Marchetti I, Ferrannini E, Miccoli P. Clin Primary cell cultures from anaplastic thyroid cancer obtained by fine-needle aspiration used for chemosensitivity tests. Endocrinol (Oxf). 2008 Jul;69(1):148-52. Epub 2008 Jul 1.
[3] Taki K, Kogai T, Kanamoto Y, Hershman JM, Brent GA. A thyroid-specific far-upstream enhancer in the human sodium/iodide symporter gene requires Pax-8 binding and cyclic adenosine 3',5'-monophosphate response element-like sequence binding proteins for full activity and is differentially regulated in normal and thyroid cancer cells. Mol Endocrinol. 2002 Oct;16(10):2266-82.